Common use of Advisory Service Clause in Contracts

Advisory Service. As a backup to the results obtained, a series of information leaflets have been generated with information about the various forms of LGMD for the patient and clinicians. Information material that was generated in conjunction with the patient charity is regularly reviewed and expanded into new areas. Advice is available on specific management and follow-up implications (which will be the responsibility of the referring clinician) and the genetic advice appropriate to the patient and other family members. Follow-up analysis of further at-risk relatives may also be indicated. This material is given to patients in clinic and/or to the referring clinician and any other clinicians involved in the care management of the patient. Gate keeping is according to clinical criteria and result of the muscle biopsy analysis. There are some exceptions (i.e. FKRP and LMNA gene), where analysis of the muscle biopsy may not be strictly necessary or even unhelpful, but for these genes we require the relevant clinical history to be provided in order to judge the relevance of the request. The service provider is engaging patients, public and patient groups in order to continuously improve the service, its design and what it offers. In this perspective, communication with public and patients group is pivotal. The provider or the service will work with NHS England to ensure sufficient considerations are given to communications. Here are listed some of the recent activities done by NHS England service for LGMDs towards public engagement, communication with patients and patients group: